David H Dreyfus

Summary

Country: USA

Publications

  1. Dreyfus D, Fraser B, Randolph C. Anaphylaxis to latex in patients without identified risk factors for latex allergy. Conn Med. 2004;68:217-22 pubmed
    ..Clinicians should consider the diagnosis of latex allergy in all cases of anaphylaxis without identified causes, even in patients without identified risk factors for latex allergy. ..
  2. Dreyfus D. Paleo-immunology: evidence consistent with insertion of a primordial herpes virus-like element in the origins of acquired immunity. PLoS ONE. 2009;4:e5778 pubmed publisher
  3. Dreyfus D. Autoimmune disease: A role for new anti-viral therapies?. Autoimmun Rev. 2011;11:88-97 pubmed publisher
    ..Other novel anti-viral therapies of chronic autoimmune diseases, such as retroviral integrase inhibitors, could be effective, although not without risk. ..
  4. Dreyfus D, Matczuk A, Fuleihan R. An RNA external guide sequence ribozyme targeting human interleukin-4 receptor alpha mRNA. Int Immunopharmacol. 2004;4:1015-27 pubmed
    ..Potential applications of inhaled RNA oligonucleotides in therapy of pulmonary and related systemic diseases are discussed. ..
  5. Dreyfus D, Nagasawa M, Gelfand E, Ghoda L. Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors. BMC Immunol. 2005;6:12 pubmed
  6. Dreyfus D. The DDE recombinases: diverse roles in acquired and innate immunity. Ann Allergy Asthma Immunol. 2006;97:567-76; quiz 576-8, 602 pubmed